Journal
FUTURE ONCOLOGY
Volume 6, Issue 9, Pages 1407-1414Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/FON.10.113
Keywords
biomarker; chemotherapy; glioblastoma; IDH1; MGMT
Categories
Funding
- Merck Serono
- Roche
- Schering Plough
- Eli Lilly
- Wyeth
- AstraZeneca
- OncoMethylomeSciences
Ask authors/readers for more resources
Significant progress has been mode in understanding the molecular pathogenesis of gliomas and in predicting general outcome depending on a limited set of clinical parameters and molecular markers. However, methylation of the O-6-methylguanine DNA methyltransferase (MGMT) gene promoter is the only molecular marker linked to sensitivity of a specific treatment, that is, alkylating agent chemotherapy, and this predictive value may be limited to glioblastoma. Moreover, in the absence of potent alternative drugs, temozolomide chemotherapy should not be withheld from patients with newly diagnosed glioblastoma without MGMT promoter methylation in general practice. In the context of clinical trials, however, irrespective of whether classical cytotoxic drugs, tyrosine kinase inhibitors or antiangiogenic agents are used, tissue should be centrally collected. Appropriate research programs should seek to define enriched patient populations for future trials and ultimately facilitate individualized cancer treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available